Navigation Links
Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment

BUSAN, South Korea, May 23, 2013 /PRNewswire/ -- Pusan National University Yangsan Hospital, in collaboration with SillaJen, Inc., a private biotherapeutics and contract research company focused on research and development of targeted biological products for cancer, announced today a publication reporting the induction of functional anti-cancer antibodies in patients treated with the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.).

This research was published in the May 15th, 2013 issue of the journal Science Translational Medicine. The co-senior and co-corresponding authors were Dr. Tae-Ho Hwang (Director of the Pusan National University Yangsan Hospital Clinical Research Center; SillaJen Chief Scientific Officer) and Dr. David Kirn (Jennerex founder and Advisor to SillaJen). The authors reported data from patients treated with JX-594 on Phase 1 and 2 clinical trials, as well as from rabbit tumor model studies. The authors demonstrated functional anti-cancer immunity induction, specifically including antibody-mediated complement-dependent cytotoxicity (CDC) in patients' serum targeting cancer cells.  Phase 1 data showed a correlation between patients' survival duration and a measure of CDC intensity. No autoimmune toxicities were reported in treated patients, including long-term survivors.

"This research was led by the laboratory group at SillaJen and Pusan National University, working closely with scientists at Jennerex. These findings, published in the premier research journal Science Translational Medicine, represent a landmark for the field of oncolytic immunotherapies for cancer," said Dr. Tae-Ho Hwang . "We were able to demonstrate for the first time that functional immune responses were induced against cancer cells following JX-594 treatment. This is an important clinical proof-of-concept for JX-594, as well as the oncolytic and immunotherapeutic approach more generally. In addition, this may represent a new paradigm for therapeutic antibody generation and identification. We believe these cutting edge experimental results demonstrate the strong translational and clinical research capabilities of SillaJen and PNU in the cancer biologics field. We will continue to leverage these capabilities as a high quality contract research organization, and for our own product pipeline in the future."

JX-594 clinical research and development is conducted in collaboration with Jennerex Inc., Green Cross Corp, Transgene, and Lee's Pharmaceuticals.

About Pusan National University Yangsan Hospital

The Pusan National University Yangsan Hospital (PNUYH) Clinical Research Center, in collaboration with SillaJen, Inc, specializes in the research and development of early-phase gene and cell therapeutics.  This development unit is composed of a highly interactive group of investigators from multiple clinical and basic science departments, providing a comprehensive and integrated framework for the development and conduct of trials in a variety of fields, with an emphasis on innovative treatment approaches.  The PNUYH CRC is supported by Pusan National University and the Korean government.

About SillaJen, Inc.

SillaJen, Inc. is a contract R&D company specializing in the translational and clinical development of complex biologics.  The SillaJen translational research, assay, and clinical research teams offer an array of services in a quality systems environment to bring investigational products from bench to bedside.  Located on the campus of Pusan National University, the company is comprised of dedicated in-house teams that collaborate closely with a network of local and USA-based world-class scientists and physicians. Born from a desire to revolutionize therapeutic approaches for patients with serious unmet medical needs and honed through years of pioneering experience guiding oncolytic vaccinia through clinical trials in Korea, the SillaJen operations are uniquely poised to assist in the development of similar cutting-edge gene and viral therapies.  Additional information about SillaJen can be found at

Media Contact:
Erica Sommermann



SOURCE Pusan National University
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
2. UV Flu Technologies Expands Its International Footprint
3. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
4. International Attendance for Networking and Education at Informex Beyond Manufacturing
5. Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses
6. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
7. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
8. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
9. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
10. PAREXEL International to Present at J.P. Morgan Healthcare Conference
11. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for Pharmaceutical Engineering ... premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place ... the largest number of attendees in more than a decade. , “The ...
Breaking Biology Technology:
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
Breaking Biology News(10 mins):